Amylyx Pharmaceuticals, Inc. (AMLX) Stock

Amylyx Pharmaceuticals, Inc. (AMLX) is a Healthcare stock trading at $15.65 (as of 2026-06-18), with a market capitalization of $1.47B and a trailing P/E of -9.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor (sodium phenylbutyrate and taurursodiol) being developed for ALS and other neurodegenerative conditions.

Valuation — source: SEC EDGAR (first-party)
Price$15.65
Market Cap$1.47B
P/E Ratio-9.9
EV / EBITDA-8.8
Price / Book5.94
Price / Sales631.21
DCF Value (model)$-16.96
DCF Upside vs Price-208.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity-55.0%
Current Ratio17.85
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)-65.5%
FCF Growth (YoY)-26.4%
Financial Health — source: SEC EDGAR
Altman Z-Score34.32 (safe)
Valuation vs Sector & Industry
Stock P/E-9.9
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-147.0%
vs Industry-157.1%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($231.16M)
Institutional Holders Tracked10
Congressional Trades (recent)1
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoshua Cohen
Employees123
CountryUS
IPO Date2022-01-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Ardelyx, Inc. (ARDX)
  • MBX Biosciences, Inc. Common Stock (MBX)
  • Tyra Biosciences, Inc. (TYRA)
  • Immatics N.V. (IMTX)
  • AnaptysBio, Inc. (ANAB)
  • Schrödinger, Inc. (SDGR)
  • Palvella Therapeutics, Inc. (PVLA)
  • Septerna, Inc. (SEPN)
AMLX earnings history · AMLX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.